12月8日 - ** 药物开发商Nurix Therapeutics NRIX.O股价盘前大涨19.6%至21.63美元
** NRIX称，在血癌药物Bexobrutideg(NX-5948) 的早期试验中，75%的患者表现出客观反应率，且副作用大多较轻
** 该药物旨在降解BTK，BTK是一种导致该疾病的蛋白质
** 如果目前的涨势得以保持，NRIX 的开盘价将达到一年后的最高点
** 截至上次收盘，该股今年累计下跌近 4
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.